JPRN-UMIN000011992
Completed
未知
Efficacy and safety of denosumab for the treatment of osteoporosis in patients with renal failure - Efficacy and safety of denosumab for the treatment of osteoporosis in patients with renal failure
ephrology Center, Toranomon Hospital Nephrology Center, Toranomon Hospital Kajigaya0 sites40 target enrollmentOctober 8, 2013
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ephrology Center, Toranomon Hospital Nephrology Center, Toranomon Hospital Kajigaya
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •CKD patients with corrected calcium (cCa)\<8\.5 mg/dl or serum PTH\> 110 pg/ml. Patients with dialysis whose serum Ca, P, and PTH are out of the range recommended by JSDT 2012 (cCa 8\.5\-10\.0 mg/dl, P 3\.5\-6\.0 mg/dl, and PTH 60\-240 pg/ml)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant settingBreast CancerJPRN-UMIN000013863Department of Endocrine and breast cancer, Kyoto Prefectural University of medicine100
Completed
Phase 2
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant settingbreast cancerJPRN-UMIN000027425Kyoto Prefectural Universuty of Medicine100
Completed
Not Applicable
The prospective study of denosumab for the treatment of osteoporosis in hemodialysis patientsOsteoporosisJPRN-UMIN000022179Yujinkai Medical Corporation Yujin-yamazaki Hospital38
Not yet recruiting
Phase 2
se of Injection Denosumab in the treatment of Giant Cell Tumour.Health Condition 1: D169- Benign neoplasm of bone and articular cartilage, unspecifiedCTRI/2024/02/062905Dr Sanyam Rathi
Active, not recruiting
Phase 1
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis. FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months)Treatment of postmenopausal osteoporosisMedDRA version: 8.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausalEUCTR2004-000138-35-GBAmgen Inc7,869